Daré Bioscience, Inc.
Daré Bioscience, Inc. DARE Peers
See (DARE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DARE | $2.52 | +5.44% | 23M | -15.26 | -$0.17 | N/A |
| VRTX | $468.85 | -2.23% | 120.4B | -123.06 | -$3.81 | N/A |
| REGN | $567.74 | +1.43% | 60.2B | 14.42 | $39.36 | +0.31% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $314.94 | -2.39% | 41B | -149.91 | -$2.10 | N/A |
| ARGX | $560.24 | -0.54% | 34.3B | 34.22 | $16.39 | N/A |
| BNTX | $112.89 | -0.90% | 27.1B | -30.03 | -$3.76 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| RPRX | $35.84 | -0.78% | 20.1B | 14.62 | $2.45 | +2.98% |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
DARE vs VRTX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, VRTX has a market cap of 120.4B. Regarding current trading prices, DARE is priced at $2.52, while VRTX trades at $468.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas VRTX's P/E ratio is -123.06. In terms of profitability, DARE's ROE is +0.47%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, DARE is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs REGN Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, REGN has a market cap of 60.2B. Regarding current trading prices, DARE is priced at $2.52, while REGN trades at $567.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas REGN's P/E ratio is 14.42. In terms of profitability, DARE's ROE is +0.47%, compared to REGN's ROE of +0.15%. Regarding short-term risk, DARE is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs SGEN Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, DARE is priced at $2.52, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas SGEN's P/E ratio is -57.19. In terms of profitability, DARE's ROE is +0.47%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, DARE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs ALNY Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, ALNY has a market cap of 41B. Regarding current trading prices, DARE is priced at $2.52, while ALNY trades at $314.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas ALNY's P/E ratio is -149.91. In terms of profitability, DARE's ROE is +0.47%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, DARE is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs ARGX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, ARGX has a market cap of 34.3B. Regarding current trading prices, DARE is priced at $2.52, while ARGX trades at $560.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas ARGX's P/E ratio is 34.22. In terms of profitability, DARE's ROE is +0.47%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, DARE is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs BNTX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, BNTX has a market cap of 27.1B. Regarding current trading prices, DARE is priced at $2.52, while BNTX trades at $112.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas BNTX's P/E ratio is -30.03. In terms of profitability, DARE's ROE is +0.47%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, DARE is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs BGNE Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, DARE is priced at $2.52, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas BGNE's P/E ratio is -22.55. In terms of profitability, DARE's ROE is +0.47%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, DARE is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs RPRX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, RPRX has a market cap of 20.1B. Regarding current trading prices, DARE is priced at $2.52, while RPRX trades at $35.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas RPRX's P/E ratio is 14.62. In terms of profitability, DARE's ROE is +0.47%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, DARE is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs DNA-WT Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, DARE is priced at $2.52, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, DARE's ROE is +0.47%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, DARE is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs SMMT Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, SMMT has a market cap of 18.6B. Regarding current trading prices, DARE is priced at $2.52, while SMMT trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas SMMT's P/E ratio is -73.53. In terms of profitability, DARE's ROE is +0.47%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, DARE is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs UTHR Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, UTHR has a market cap of 13.3B. Regarding current trading prices, DARE is priced at $2.52, while UTHR trades at $295.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas UTHR's P/E ratio is 11.78. In terms of profitability, DARE's ROE is +0.47%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, DARE is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs INCY Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, INCY has a market cap of 13.3B. Regarding current trading prices, DARE is priced at $2.52, while INCY trades at $68.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas INCY's P/E ratio is 343.10. In terms of profitability, DARE's ROE is +0.47%, compared to INCY's ROE of +0.01%. Regarding short-term risk, DARE is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs GMAB Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, GMAB has a market cap of 13.2B. Regarding current trading prices, DARE is priced at $2.52, while GMAB trades at $21.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas GMAB's P/E ratio is 12.59. In terms of profitability, DARE's ROE is +0.47%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, DARE is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs MRNA Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, MRNA has a market cap of 13B. Regarding current trading prices, DARE is priced at $2.52, while MRNA trades at $33.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas MRNA's P/E ratio is -3.85. In terms of profitability, DARE's ROE is +0.47%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, DARE is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs KRTX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, DARE is priced at $2.52, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas KRTX's P/E ratio is -28.09. In terms of profitability, DARE's ROE is +0.47%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, DARE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs EXEL Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, EXEL has a market cap of 12.2B. Regarding current trading prices, DARE is priced at $2.52, while EXEL trades at $44.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas EXEL's P/E ratio is 20.49. In terms of profitability, DARE's ROE is +0.47%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, DARE is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs BMRN Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, DARE is priced at $2.52, while BMRN trades at $58.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas BMRN's P/E ratio is 21.51. In terms of profitability, DARE's ROE is +0.47%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, DARE is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs ASND Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, ASND has a market cap of 10.6B. Regarding current trading prices, DARE is priced at $2.52, while ASND trades at $174.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas ASND's P/E ratio is -25.58. In terms of profitability, DARE's ROE is +0.47%, compared to ASND's ROE of +1.91%. Regarding short-term risk, DARE is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs RXDX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, DARE is priced at $2.52, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas RXDX's P/E ratio is -56.47. In terms of profitability, DARE's ROE is +0.47%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, DARE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs VRNA Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, DARE is priced at $2.52, while VRNA trades at $104.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas VRNA's P/E ratio is -52.41. In terms of profitability, DARE's ROE is +0.47%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, DARE is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs BBIO Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, BBIO has a market cap of 8.8B. Regarding current trading prices, DARE is priced at $2.52, while BBIO trades at $46.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas BBIO's P/E ratio is -13.06. In terms of profitability, DARE's ROE is +0.47%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, DARE is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs IMGN Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, DARE is priced at $2.52, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas IMGN's P/E ratio is -111.55. In terms of profitability, DARE's ROE is +0.47%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, DARE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs TECH Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, TECH has a market cap of 8.5B. Regarding current trading prices, DARE is priced at $2.52, while TECH trades at $54.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas TECH's P/E ratio is 65.23. In terms of profitability, DARE's ROE is +0.47%, compared to TECH's ROE of +0.06%. Regarding short-term risk, DARE is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs BPMC Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, DARE is priced at $2.52, while BPMC trades at $129.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas BPMC's P/E ratio is -51.52. In terms of profitability, DARE's ROE is +0.47%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, DARE is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs CERE Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, DARE is priced at $2.52, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas CERE's P/E ratio is -16.47. In terms of profitability, DARE's ROE is +0.47%, compared to CERE's ROE of -0.43%. Regarding short-term risk, DARE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs ROIVW Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, DARE is priced at $2.52, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, DARE's ROE is +0.47%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, DARE is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs ROIV Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, ROIV has a market cap of 7.7B. Regarding current trading prices, DARE is priced at $2.52, while ROIV trades at $11.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas ROIV's P/E ratio is -15.15. In terms of profitability, DARE's ROE is +0.47%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, DARE is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs CORT Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, DARE is priced at $2.52, while CORT trades at $71.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas CORT's P/E ratio is 62.50. In terms of profitability, DARE's ROE is +0.47%, compared to CORT's ROE of +0.20%. Regarding short-term risk, DARE is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs RVMD Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, RVMD has a market cap of 7.1B. Regarding current trading prices, DARE is priced at $2.52, while RVMD trades at $38.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas RVMD's P/E ratio is -9.48. In terms of profitability, DARE's ROE is +0.47%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, DARE is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs HALO Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, HALO has a market cap of 7B. Regarding current trading prices, DARE is priced at $2.52, while HALO trades at $57.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas HALO's P/E ratio is 15.20. In terms of profitability, DARE's ROE is +0.47%, compared to HALO's ROE of +1.22%. Regarding short-term risk, DARE is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs MDGL Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, MDGL has a market cap of 7B. Regarding current trading prices, DARE is priced at $2.52, while MDGL trades at $315.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas MDGL's P/E ratio is -16.51. In terms of profitability, DARE's ROE is +0.47%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, DARE is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs AMRN Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, AMRN has a market cap of 7B. Regarding current trading prices, DARE is priced at $2.52, while AMRN trades at $16.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas AMRN's P/E ratio is -3.85. In terms of profitability, DARE's ROE is +0.47%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, DARE is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs JAZZ Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, JAZZ has a market cap of 6.7B. Regarding current trading prices, DARE is priced at $2.52, while JAZZ trades at $110.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas JAZZ's P/E ratio is 14.99. In terms of profitability, DARE's ROE is +0.47%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, DARE is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs IONS Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, IONS has a market cap of 6.6B. Regarding current trading prices, DARE is priced at $2.52, while IONS trades at $41.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas IONS's P/E ratio is -13.96. In terms of profitability, DARE's ROE is +0.47%, compared to IONS's ROE of -0.92%. Regarding short-term risk, DARE is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs RETA Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, DARE is priced at $2.52, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas RETA's P/E ratio is -66.29. In terms of profitability, DARE's ROE is +0.47%, compared to RETA's ROE of +0.47%. Regarding short-term risk, DARE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs TGTX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, TGTX has a market cap of 5.9B. Regarding current trading prices, DARE is priced at $2.52, while TGTX trades at $37.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas TGTX's P/E ratio is 148.34. In terms of profitability, DARE's ROE is +0.47%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, DARE is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs ABCM Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, DARE is priced at $2.52, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, DARE's ROE is +0.47%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, DARE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs RYTM Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, RYTM has a market cap of 5.5B. Regarding current trading prices, DARE is priced at $2.52, while RYTM trades at $86.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas RYTM's P/E ratio is -30.99. In terms of profitability, DARE's ROE is +0.47%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, DARE is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs ISEE Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, DARE is priced at $2.52, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas ISEE's P/E ratio is -22.44. In terms of profitability, DARE's ROE is +0.47%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, DARE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs TLX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, TLX has a market cap of 5.4B. Regarding current trading prices, DARE is priced at $2.52, while TLX trades at $15.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas TLX's P/E ratio is 177.44. In terms of profitability, DARE's ROE is +0.47%, compared to TLX's ROE of +0.14%. Regarding short-term risk, DARE is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs AXSM Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, AXSM has a market cap of 5.4B. Regarding current trading prices, DARE is priced at $2.52, while AXSM trades at $108.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas AXSM's P/E ratio is -18.54. In terms of profitability, DARE's ROE is +0.47%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, DARE is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs NUVL Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, NUVL has a market cap of 5.4B. Regarding current trading prices, DARE is priced at $2.52, while NUVL trades at $80.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas NUVL's P/E ratio is -18.29. In terms of profitability, DARE's ROE is +0.47%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, DARE is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs ALKS Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, ALKS has a market cap of 5B. Regarding current trading prices, DARE is priced at $2.52, while ALKS trades at $30.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas ALKS's P/E ratio is 14.41. In terms of profitability, DARE's ROE is +0.47%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, DARE is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs CRSP Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, DARE is priced at $2.52, while CRSP trades at $56.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas CRSP's P/E ratio is -12.65. In terms of profitability, DARE's ROE is +0.47%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, DARE is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs PCVX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, PCVX has a market cap of 4.6B. Regarding current trading prices, DARE is priced at $2.52, while PCVX trades at $35.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas PCVX's P/E ratio is -9.00. In terms of profitability, DARE's ROE is +0.47%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, DARE is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs ALPN Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, DARE is priced at $2.52, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas ALPN's P/E ratio is -101.52. In terms of profitability, DARE's ROE is +0.47%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, DARE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs CYTK Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, DARE is priced at $2.52, while CYTK trades at $37.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas CYTK's P/E ratio is -7.00. In terms of profitability, DARE's ROE is +0.47%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, DARE is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs ADMA Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, ADMA has a market cap of 4.4B. Regarding current trading prices, DARE is priced at $2.52, while ADMA trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas ADMA's P/E ratio is 22.02. In terms of profitability, DARE's ROE is +0.47%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, DARE is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs KRYS Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, KRYS has a market cap of 4.3B. Regarding current trading prices, DARE is priced at $2.52, while KRYS trades at $148.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas KRYS's P/E ratio is 35.64. In terms of profitability, DARE's ROE is +0.47%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, DARE is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs OPT Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, DARE is priced at $2.52, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas OPT's P/E ratio is -1.52. In terms of profitability, DARE's ROE is +0.47%, compared to OPT's ROE of +2.60%. Regarding short-term risk, DARE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs MTSR Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, MTSR has a market cap of 4.1B. Regarding current trading prices, DARE is priced at $2.52, while MTSR trades at $39.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas MTSR's P/E ratio is -15.48. In terms of profitability, DARE's ROE is +0.47%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, DARE is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs MRTX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, DARE is priced at $2.52, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas MRTX's P/E ratio is -4.82. In terms of profitability, DARE's ROE is +0.47%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, DARE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs AKRO Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, AKRO has a market cap of 4.1B. Regarding current trading prices, DARE is priced at $2.52, while AKRO trades at $51.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas AKRO's P/E ratio is -13.75. In terms of profitability, DARE's ROE is +0.47%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, DARE is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs SLNO Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, SLNO has a market cap of 4.1B. Regarding current trading prices, DARE is priced at $2.52, while SLNO trades at $81.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas SLNO's P/E ratio is -17.20. In terms of profitability, DARE's ROE is +0.47%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, DARE is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs MRUS Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, MRUS has a market cap of 4.1B. Regarding current trading prices, DARE is priced at $2.52, while MRUS trades at $54.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas MRUS's P/E ratio is -13.10. In terms of profitability, DARE's ROE is +0.47%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, DARE is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs PTCT Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, DARE is priced at $2.52, while PTCT trades at $48.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas PTCT's P/E ratio is 7.46. In terms of profitability, DARE's ROE is +0.47%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, DARE is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs ACLX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, ACLX has a market cap of 3.8B. Regarding current trading prices, DARE is priced at $2.52, while ACLX trades at $68.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas ACLX's P/E ratio is -23.04. In terms of profitability, DARE's ROE is +0.47%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, DARE is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs RNA Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, RNA has a market cap of 3.8B. Regarding current trading prices, DARE is priced at $2.52, while RNA trades at $31.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas RNA's P/E ratio is -10.50. In terms of profitability, DARE's ROE is +0.47%, compared to RNA's ROE of -0.27%. Regarding short-term risk, DARE is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs RYZB Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, DARE is priced at $2.52, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas RYZB's P/E ratio is -57.86. In terms of profitability, DARE's ROE is +0.47%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, DARE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs CBAY Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, DARE is priced at $2.52, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas CBAY's P/E ratio is -32.81. In terms of profitability, DARE's ROE is +0.47%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, DARE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs ZLAB Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, ZLAB has a market cap of 3.6B. Regarding current trading prices, DARE is priced at $2.52, while ZLAB trades at $32.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas ZLAB's P/E ratio is -13.08. In terms of profitability, DARE's ROE is +0.47%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, DARE is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs LEGN Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, LEGN has a market cap of 3.6B. Regarding current trading prices, DARE is priced at $2.52, while LEGN trades at $38.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas LEGN's P/E ratio is -33.03. In terms of profitability, DARE's ROE is +0.47%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, DARE is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs SRRK Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, SRRK has a market cap of 3.6B. Regarding current trading prices, DARE is priced at $2.52, while SRRK trades at $37.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas SRRK's P/E ratio is -14.67. In terms of profitability, DARE's ROE is +0.47%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, DARE is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs SWTX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, DARE is priced at $2.52, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas SWTX's P/E ratio is -13.78. In terms of profitability, DARE's ROE is +0.47%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, DARE is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs ACAD Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, ACAD has a market cap of 3.5B. Regarding current trading prices, DARE is priced at $2.52, while ACAD trades at $20.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas ACAD's P/E ratio is 15.31. In terms of profitability, DARE's ROE is +0.47%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, DARE is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs VKTX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, VKTX has a market cap of 3.5B. Regarding current trading prices, DARE is priced at $2.52, while VKTX trades at $31.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas VKTX's P/E ratio is -26.82. In terms of profitability, DARE's ROE is +0.47%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, DARE is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs AAPG Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, AAPG has a market cap of 3.3B. Regarding current trading prices, DARE is priced at $2.52, while AAPG trades at $38.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas AAPG's P/E ratio is -51.13. In terms of profitability, DARE's ROE is +0.47%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, DARE is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs PTGX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, DARE is priced at $2.52, while PTGX trades at $53.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas PTGX's P/E ratio is 67.97. In terms of profitability, DARE's ROE is +0.47%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, DARE is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs KYMR Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, KYMR has a market cap of 3.1B. Regarding current trading prices, DARE is priced at $2.52, while KYMR trades at $44.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas KYMR's P/E ratio is -14.30. In terms of profitability, DARE's ROE is +0.47%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, DARE is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs MLTX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, MLTX has a market cap of 3.1B. Regarding current trading prices, DARE is priced at $2.52, while MLTX trades at $49.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas MLTX's P/E ratio is -21.33. In terms of profitability, DARE's ROE is +0.47%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, DARE is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs IMVT Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, IMVT has a market cap of 3.1B. Regarding current trading prices, DARE is priced at $2.52, while IMVT trades at $18.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas IMVT's P/E ratio is -6.64. In terms of profitability, DARE's ROE is +0.47%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, DARE is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs CRNX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, CRNX has a market cap of 3B. Regarding current trading prices, DARE is priced at $2.52, while CRNX trades at $31.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas CRNX's P/E ratio is -8.40. In terms of profitability, DARE's ROE is +0.47%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, DARE is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs NAMSW Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, NAMSW has a market cap of 2.9B. Regarding current trading prices, DARE is priced at $2.52, while NAMSW trades at $10.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas NAMSW's P/E ratio is N/A. In terms of profitability, DARE's ROE is +0.47%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, DARE is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs MORF Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, DARE is priced at $2.52, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas MORF's P/E ratio is -14.88. In terms of profitability, DARE's ROE is +0.47%, compared to MORF's ROE of -0.22%. Regarding short-term risk, DARE is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs MOR Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, DARE is priced at $2.52, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas MOR's P/E ratio is -12.64. In terms of profitability, DARE's ROE is +0.47%, compared to MOR's ROE of -1.84%. Regarding short-term risk, DARE is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs RARE Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, RARE has a market cap of 2.8B. Regarding current trading prices, DARE is priced at $2.52, while RARE trades at $29.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas RARE's P/E ratio is -5.06. In terms of profitability, DARE's ROE is +0.47%, compared to RARE's ROE of -1.86%. Regarding short-term risk, DARE is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs KDNY Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, DARE is priced at $2.52, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas KDNY's P/E ratio is -12.47. In terms of profitability, DARE's ROE is +0.47%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, DARE is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs CPRX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, CPRX has a market cap of 2.7B. Regarding current trading prices, DARE is priced at $2.52, while CPRX trades at $21.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas CPRX's P/E ratio is 13.89. In terms of profitability, DARE's ROE is +0.47%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, DARE is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs MYOV Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, DARE is priced at $2.52, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas MYOV's P/E ratio is -14.05. In terms of profitability, DARE's ROE is +0.47%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, DARE is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs MIRM Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, DARE is priced at $2.52, while MIRM trades at $52.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas MIRM's P/E ratio is -32.71. In terms of profitability, DARE's ROE is +0.47%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, DARE is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs ARWR Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, ARWR has a market cap of 2.5B. Regarding current trading prices, DARE is priced at $2.52, while ARWR trades at $18.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas ARWR's P/E ratio is -14.77. In terms of profitability, DARE's ROE is +0.47%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, DARE is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs IBRX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, IBRX has a market cap of 2.5B. Regarding current trading prices, DARE is priced at $2.52, while IBRX trades at $2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas IBRX's P/E ratio is -4.91. In terms of profitability, DARE's ROE is +0.47%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, DARE is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs XENE Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, XENE has a market cap of 2.5B. Regarding current trading prices, DARE is priced at $2.52, while XENE trades at $32.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas XENE's P/E ratio is -10.00. In terms of profitability, DARE's ROE is +0.47%, compared to XENE's ROE of -0.32%. Regarding short-term risk, DARE is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs APLS Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, APLS has a market cap of 2.4B. Regarding current trading prices, DARE is priced at $2.52, while APLS trades at $19.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas APLS's P/E ratio is -10.81. In terms of profitability, DARE's ROE is +0.47%, compared to APLS's ROE of -1.00%. Regarding short-term risk, DARE is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs NAMS Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, NAMS has a market cap of 2.4B. Regarding current trading prices, DARE is priced at $2.52, while NAMS trades at $21.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas NAMS's P/E ratio is -11.70. In terms of profitability, DARE's ROE is +0.47%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, DARE is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs PRVB Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, DARE is priced at $2.52, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas PRVB's P/E ratio is -16.43. In terms of profitability, DARE's ROE is +0.47%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, DARE is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs LGND Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, LGND has a market cap of 2.4B. Regarding current trading prices, DARE is priced at $2.52, while LGND trades at $121.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas LGND's P/E ratio is -16.71. In terms of profitability, DARE's ROE is +0.47%, compared to LGND's ROE of -0.16%. Regarding short-term risk, DARE is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs LBPH Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, DARE is priced at $2.52, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas LBPH's P/E ratio is -26.66. In terms of profitability, DARE's ROE is +0.47%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, DARE is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs APGE Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, APGE has a market cap of 2.3B. Regarding current trading prices, DARE is priced at $2.52, while APGE trades at $38.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas APGE's P/E ratio is -10.57. In terms of profitability, DARE's ROE is +0.47%, compared to APGE's ROE of -0.19%. Regarding short-term risk, DARE is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs DICE Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, DARE is priced at $2.52, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas DICE's P/E ratio is -21.91. In terms of profitability, DARE's ROE is +0.47%, compared to DICE's ROE of +0.56%. Regarding short-term risk, DARE is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs AGIO Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, AGIO has a market cap of 2.3B. Regarding current trading prices, DARE is priced at $2.52, while AGIO trades at $39.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas AGIO's P/E ratio is 3.39. In terms of profitability, DARE's ROE is +0.47%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, DARE is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs CALT Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, DARE is priced at $2.52, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas CALT's P/E ratio is -22.73. In terms of profitability, DARE's ROE is +0.47%, compared to CALT's ROE of -1.67%. Regarding short-term risk, DARE is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs BEAM Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, BEAM has a market cap of 2.1B. Regarding current trading prices, DARE is priced at $2.52, while BEAM trades at $21.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas BEAM's P/E ratio is -4.59. In terms of profitability, DARE's ROE is +0.47%, compared to BEAM's ROE of -0.44%. Regarding short-term risk, DARE is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs VCYT Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, DARE is priced at $2.52, while VCYT trades at $27.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas VCYT's P/E ratio is 64.45. In terms of profitability, DARE's ROE is +0.47%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, DARE is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs RXRX Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, RXRX has a market cap of 2.1B. Regarding current trading prices, DARE is priced at $2.52, while RXRX trades at $5.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas RXRX's P/E ratio is -3.14. In terms of profitability, DARE's ROE is +0.47%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, DARE is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs DNLI Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, DNLI has a market cap of 2.1B. Regarding current trading prices, DARE is priced at $2.52, while DNLI trades at $14.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas DNLI's P/E ratio is -5.44. In terms of profitability, DARE's ROE is +0.47%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, DARE is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs BLTE Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, BLTE has a market cap of 2.1B. Regarding current trading prices, DARE is priced at $2.52, while BLTE trades at $63.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas BLTE's P/E ratio is -46.43. In terms of profitability, DARE's ROE is +0.47%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, DARE is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs KNSA Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, KNSA has a market cap of 2B. Regarding current trading prices, DARE is priced at $2.52, while KNSA trades at $28.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas KNSA's P/E ratio is -117.00. In terms of profitability, DARE's ROE is +0.47%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, DARE is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.
DARE vs CGON Comparison
DARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DARE stands at 23M. In comparison, CGON has a market cap of 2B. Regarding current trading prices, DARE is priced at $2.52, while CGON trades at $26.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DARE currently has a P/E ratio of -15.26, whereas CGON's P/E ratio is -18.05. In terms of profitability, DARE's ROE is +0.47%, compared to CGON's ROE of -0.17%. Regarding short-term risk, DARE is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for DARE.